Experimental GLS-1 inhibitor demonstrates antitumor activity in advanced treatment-resistant ovarian cancer
Combining the experimental therapy IACS-6274 with targeted therapy bevacizumab and paclitaxel chemotherapy showed promising antitumor activity in a Phase I trial of patients with advanced platinum-resistant ovarian cancer, according to new results presented by researchers from The University of Texas MD Anderson Cancer Center.
Read original article on Medical Xpress - latest medical and health news stories →